Combining PD-L1 blockade with immunogenic cell death induced by AIE photosensitizer to improve antitumor immunity

被引:28
|
作者
Li, Jianqing [1 ]
Dai, Jun [2 ]
Zhuang, Zeyan [1 ]
Meng, Zijuan [3 ]
Hu, Jing-Jing [3 ]
Lou, Xiaoding [3 ]
Xia, Fan [3 ]
Zhao, Zujin [1 ]
Tang, Ben Zhong [1 ,4 ]
机构
[1] South China Univ Technol, Guangdong Prov Key Lab Luminescence Mol Aggregates, State Key Lab Luminescent Mat & Devices, Guangzhou 510640, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan 430034, Peoples R China
[3] China Univ Geosci, Fac Mat Sci & Chem, Key Lab Biogeol & Environm Geol, Wuhan 430074, Peoples R China
[4] Chinese Univ Hong Kong, Shenzhen Inst Aggregate Sci & Technol, Sch Sci & Engn, Shenzhen 518172, Guangdong, Peoples R China
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
Photodynamic therapy; Immunogenic cell death; Endoplasmic reticulum stress; Immune checkpoint blockade; Aggregation-induced emission; AGGREGATION-INDUCED EMISSION; PHOTODYNAMIC THERAPY; CANCER-IMMUNOTHERAPY; GENERATION; AUTOPHAGY; STRESS;
D O I
10.1016/j.biomaterials.2022.121899
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Immunogenic cell death (ICD) is considered an effective death mode to trigger immune response. However, the currently available efficient ICD inducers are quite limited. Endoplasmic reticulum (ER) stress is known as the precursor of ICD, which can be directly triggered by reactive oxygen species in situ. Herein, a novel photosen-sitizer (alpha-Th-TPA-PIO) based on phosphindole oxide, featuring aggregation-induced emission (AIE) is designed and prepared, which possesses good ability of hydroxyl radicals (HO center dot) generation. Besides, alpha-Th-TPA-PIO can selectively accumulate in ER and trigger ER stress under white light irradiation, further leading to effective ICD. Combining with anti-programmed death-ligand 1 (anti-PD-L1), the synergistic effect of photodynamic therapy (PDT) and immune checkpoint blockade can achieve a significantly enhanced inhibition effect on the growth of tumors and simultaneously provoke a systemic antitumor immune response. Notably, by adopting this thera-peutic strategy to bilateral and metastatic tumor models, the growth of both primary and distant subcutaneous tumors can be successfully suppressed, and metastatic tumor can also be inhibited to some degree. Taken together, this work not only provides a novel ICD photoinducer based on PDT, but also brings about a useful immunomodulatory strategy to realize superior antitumor effect.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
    Kepp, Oliver
    Zitvogel, Laurence
    Kroemer, Guido
    ONCOIMMUNOLOGY, 2019, 8 (10):
  • [2] PD-L1 antibody conjugated dihydrotanshinone I-loaded polymeric nanoparticle for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
    Wang, Xue
    Jing, Ziqi
    Huang, Xiaobin
    Liu, Xiaoya
    Zhang, Yujie
    Wang, Zhijun
    Ma, Pengkai
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 667
  • [3] Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
    Moon, Yujeong
    Shim, Man Kyu
    Choi, Jiwoong
    Yang, Suah
    Kim, Jinseong
    Yun, Wan Su
    Cho, Hanhee
    Park, Jung Yeon
    Kim, Yongju
    Seong, Joon-Kyung
    Kim, Kwangmeyung
    THERANOSTICS, 2022, 12 (05): : 1999 - 2014
  • [4] Near-Infrared II Nanoadjuvant-Mediated Chemodynamic, Photodynamic, and Photothermal Therapy Combines Immunogenic Cell Death with PD-L1 Blockade to Enhance Antitumor Immunity
    Xiang, Qinyanqiu
    Yang, Chao
    Luo, Yuanli
    Liu, Fan
    Zheng, Jun
    Liu, Weiwei
    Ran, Haitao
    Sun, Yang
    Ren, Jianli
    Wang, Zhigang
    SMALL, 2022, 18 (13)
  • [5] Celastrol Elicits Antitumor Effects through Inducing Immunogenic Cell Death and Downregulating PD-L1 in ccRCC
    Li, Hong-Fang
    Zhu, Neng
    Wu, Jia-Jun
    Shi, Ya-Ning
    Gu, Jia
    Qin, Li
    CURRENT PHARMACEUTICAL DESIGN, 2024, 30 (16) : 1265 - 1278
  • [6] Enhanced Immunogenic Cell Death by Apoptosis/Ferroptosis Hybrid Pathway Potentiates PD-L1 Blockade Cancer Immunotherapy
    Jeong, Seong Dong
    Jung, Bo-Kyeong
    Lee, DaeYong
    Ha, JongHoon
    Chang, Han-Gyu
    Lee, Jeongmin
    Lee, Susam
    Yun, Chae-Ok
    Kim, Yeu-Chun
    ACS BIOMATERIALS SCIENCE & ENGINEERING, 2022, 8 (12): : 5188 - 5198
  • [7] Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity
    Zhang, Yuankun
    Song, Qingxiao
    Cassady, Kaniel
    Lee, Michael
    Tang, Haidong
    Zheng, Moqian
    Wang, Bixin
    Schones, Dustin E.
    Fu, Yang-Xin
    Riggs, Arthur D.
    Martin, Paul J.
    Feng, Ru
    Zeng, Defu
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (16)
  • [8] Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer
    Chang, Jie
    Quan, Shimin
    Tian, Sijuan
    Wang, Shirui
    Li, Simin
    Guo, Yanping
    Yang, Ting
    Yang, Xiaofeng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (06)
  • [9] Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade
    Mitsuhashi, Atsushi
    Koyama, Kazuya
    Ogino, Hirokazu
    Afroj, Tania
    Nguyen, Na Thi
    Yoneda, Hiroto
    Otsuka, Kenji
    Sugimoto, Masamichi
    Kondoh, Osamu
    Nokihara, Hiroshi
    Hanibuchi, Masak
    Takizawa, Hiromitsu
    Shinohara, Tsutomu
    Nishioka, Yasuhiko
    CELL REPORTS, 2023, 42 (03):
  • [10] Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma
    Nan, Yanyang
    Zhang, Xuyao
    Wang, Shaofei
    Xu, Caili
    Wang, Yichen
    Han, Lei
    Luan, Jingyun
    Hu, Xiaozhi
    Chen, Wei
    Cao, Zhonglian
    Zhu, Zeguo
    Zeng, Xian
    Fan, Jiajun
    Ye, Li
    Shi, Xunlong
    Ju, Dianwen
    IMMUNOTHERAPY, 2023, 15 (03) : 175 - 187